Skip to content

Study · Non-randomized trial · n = 17 · 1985

4 results

The use of growth hormone-releasing hormone in the diagnosis and treatment of short stature.

Grossman A, Savage MO, Blacklay A, Ross RM, Plowman PN, Preece MA, Coy DH, Besser GM

Hormone research1 Jan 1985Cited by 17 (Europe PMC)

PMID2863206 (opens in a new tab)DOI10.1159/000180071 (opens in a new tab)PepBankPUB-02863206
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    After a 200 microgram GHRH bolus, serum GH rose to normal or just subnormal levels in 13 of 17 children with structural lesions.

    In plain wordsAfter one GHRH dose, growth hormone rose to a normal or near-normal level in 13 of 17 children with structural brain lesions.

    Peptide
    Sermorelin
    Outcome
    IncreaseSerum GH response to GHRH bolus in children with structural lesions
    Study

    n = 17

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    200 micrograms · intravenous bolus · single doseAs given in this study (human).

    Measurements

    Children with serum GH rising to normal or just subnormal levels
    13 of 17
    structural lesions

    Source sentences

    Summary
    Following 200 micrograms GHRH as an acute intravenous bolus, serum GH rose to normal or just subnormal levels in 13 out of 17 children with structural lesions
    1 context sentence
    Summary · context
    We have assessed the role of growth hormone-releasing hormone (GHRH) as a diagnostic test in 40 children and young adults with growth hormone deficiency (GHD), principally using the GHRH(1-29)NH2 analogue.
  2. 02HumanNon-randomized trialEfficacy outcome

    After a 200 microgram GHRH bolus, serum GH rose to normal or just subnormal levels in 8 of 14 patients with idiopathic GHD or panhypopituitarism.

    In plain wordsAfter one GHRH dose, growth hormone rose to a normal or near-normal level in 8 of 14 patients with idiopathic deficiency or pituitary failure.

    Peptide
    Sermorelin
    Outcome
    IncreaseSerum GH response to GHRH bolus in idiopathic GHD or panhypopituitarism
    Study

    n = 14

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    200 micrograms · intravenous bolus · single doseAs given in this study (human).

    Measurements

    Patients with serum GH rising to normal or just subnormal levels
    8 of 14
    idiopathic GHD or panhypopituitarism

    Source sentences

    Summary
    in 8 of 14 patients with idiopathic GHD or panhypopituitarism.
    1 context sentence
    Summary · context
    We have assessed the role of growth hormone-releasing hormone (GHRH) as a diagnostic test in 40 children and young adults with growth hormone deficiency (GHD), principally using the GHRH(1-29)NH2 analogue.
  3. 03HumanNon-randomized trialEfficacy outcome

    All 9 children with GHD after cranial irradiation for nonendocrine tumours responded acutely to GHRH.

    In plain wordsAll 9 children with growth hormone deficiency after head radiation had a growth hormone rise after GHRH.

    Peptide
    Sermorelin
    Outcome
    IncreaseAcute GH response in children with GHD after cranial irradiation
    Study

    n = 9

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Children responding acutely to GHRH
    9 children
    GHD after cranial irradiation

    Source sentences

    Summary
    Of 9 children (mean age 12 years) with GHD following treatment with cranial irradiation for nonendocrine tumours, all responded acutely to GHRH.
    1 context sentence
    Summary · context
    We have assessed the role of growth hormone-releasing hormone (GHRH) as a diagnostic test in 40 children and young adults with growth hormone deficiency (GHD), principally using the GHRH(1-29)NH2 analogue.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with GHD, 12- and 24-hour infusions and 1- and 2-week twice-daily subcutaneous GHRH(1-29)NH2 showed persistent stimulation of GH release.

    In plain wordsIn patients with growth hormone deficiency, GHRH infusions and one to two weeks of injections kept growth hormone release going.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH release during GHRH(1-29)NH2 infusion and short-term subcutaneous treatment
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · infusion and subcutaneous · 12- and 24-hour infusions; 1- and 2-week treatmentsAs given in this study (human).

    Source sentences

    Summary
    12- and 24-hour infusions with GHRH(1-29)NH2, and 1- and 2-week treatments with twice-daily subcutaneous GHRH(1-29)NH2, showed persistent stimulation of GH release.
    1 context sentence
    Summary · context
    We have assessed the role of growth hormone-releasing hormone (GHRH) as a diagnostic test in 40 children and young adults with growth hormone deficiency (GHD), principally using the GHRH(1-29)NH2 analogue.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.